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Abstract: 
Objective:  In this study we investigate the effectiveness of lycopene in the management of oral submucous 
fibrosis (OSF) when intralesional steroids also given in combination. Methodology: This cross sectional study 
was done in Dental Section Allied Hospital, Faisalabad, Fatima Jinnah Hospital, Multan and Nishtar Institute of 
Dentistry, Multan  in duration of six months from September 2017 to April 2018. This cross sectional study was 
initiated after approval from hospital ethical board. Collected Information was entered in SPSS computer software 
version 23.1 and analyzed for possible results. Mean and SD was calculated and presented for quantitative data 
like age, VAS score and mouth opening. Frequency (percentages) were calculated and presented for qualitative 
data such as gender. Post stratification statistical chi square test was used to see effect modification. P value ≤ 0.05 
was considered as significant. Results: Overall, there were 100% (n=354) patients. Total patients who were 
selected for the study had the habit of chewing areca nut either in natural form or in the form of Pan Masala, gutkha 
or mawa. Gutkha is the most common form of areca nut used, i.e. 65.8% (n=233) patients were using it. In pour 
study average increase in mouth opening from baseline (before treatment) was 2.34±1.03 mm in group A. 
4.20±1.26 mm in group B and 3.40±0.19 mm in group C at six week. Conclusion: When Lycopene used combined 
with intralesional steroids and Hyaluronidase its effectiveness is better in improving the mouth opening its 
symptoms in patients with Oral Submucous Fibrosis (OSF). It was also found that there was no side effects. 
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Introduction  
Oral sebaceous fibrosis (OSF) is a malignant disease of oral cavity sometime chronic in nature and may affect 
pharynx (1). From last few years it is a conflict of interest and under debate issue due to its chronic resistant nature. 
In Asia OSF was predominantly found in Indian population (2). In many studies various factors were reported 
such as ; hypersensitivity, deficiency of vitamin B12, capsaicin, autoimmunity, chronic iron deficiency and betel 
nut alkaloids, most common of which is chewing areca (3). Chewing areca increase the formation of collagen that 
stimulates production of free radicals in body which may lead to fibrosis. Increase production of free radicals also 
responsible for high oxidation of fatty acids and affects contents of cell membrane which may results tumor 
formation (4). Areca chewing is a common mouth freshener used in Indian community and have deep roots in their 
history. Excessive use of areca chewing an(5)d its contents ulcerate the cell structures like, nucleic acid, lipids, 
proteins and cell membrane (6). Its use also denatured the vitamins, creates malnutrition and damages the mucosa 
of oral cavity (7, 8). When dentists concern about its treatment modalities antioxidants are the best choices which 
stabilize free radicals in early phase of cell involvement. A most effective antioxidant is lycopene, synthesized by 
the plants and microorganisms. Lycopene is stronger antioxidant than alpha tocopherol (lycopene is ten times 
stronger) and beta carotenes (lycopene is twice more stronger) (9, 10). Among available antioxidants no one have 
ability. 
Methodology:  
This cross sectional study was done Dental Section Allied Hospital, Faisalabad, Fatima Jinnah Hospital, Multan 
and Nishtar Institute of Dentistry, Multan in duration of six months from September 2017 to April 2018. This cross 
sectional study was initiated after approval from hospital ethical board; informed written consent was obtained 
from patients or their attendants and ensured about confidentiality/privacy. Sample size of study was calculated 
with WHO approved sample size calculator by using following characteristics: Confidence Interval 95%, Power 
of study 80% proportion of accuracy use (p) 64.4% by using non probability consecutive sampling technique. 
Patients with history of chewing arecanut and its products, burning on ingestion of fast food, limited mouth opening 
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without use of band (palpable and non palpable) were included in the study. Patients of malignant OSF diagnosed 
histologically were excluded from the study.   
 
After complete prophylaxis and detailed information about severity and malignancy condition patients were 
counseled to stop chewing arecanut. Total number of patients were grouped as group A, B and C. patients in group 
A were treated with Lycopene capsule (16mg), single capsule daily and dexamethasone 1.5 mg and “Hyaluronidase 
1500 IU mixed with lignocaine injection” two times in a week. Group B were given oral multivitamins daily plus 
intralesional dexamethasone injection 1.5 mg two times in a week and Hyaluronidase 1500 IU mixed with 
lignocaine. In group C patients were given only weekly intralesional injections of Dexamethasone 1.5 ml & 
Hyaluronidase 1500 IU with lignocaine two times in a week without any other supplement. All patients were 
followed up upto six weeks and evaluated at every week for; Habits, mouth opening and burning sensation. All 
parameters were recorded before start of treatment and considered as baseline and then on every week for 
comparison of betterment. Burning sensation was measured by measuring VAS score. Size of mouth opening was 
recorded by measurement of interincisal distance from the mesioincisal edge of the maxillary right central incisor 
to the mesioincisal edge of the mandibular right central incisor by using a measuring instrument (vernier calipers). 
If any tooth was missing other side was used for measurement of distance or mouth opening. 
 
Collected Information was entered in SPSS computer software version 23.1 and analyzed for possible results. 
Mean and SD was calculated and presented for quantitative data like age, VAS score and mouth opening. 
Frequency (percentages) were calculated and presented for qualitative data such as gender. Post stratification 
statistical chi square test was used to see effect modification. P value ≤ 0.05 was considered as significant. 
Results: 
 Overall, there were 100% (n=354) patients. Patients with habit of chewing areca nut and its products like; 
mawa, Pan Masala and gutka were included in the study. About 65.8% patients have habit of chewing gutka. 
Duration of habits was 5.06±2.01 years. (Range: 1 to 12 years). 
The study population was subdivided into three groups; 33.33% (n=118) in each of the three groups. The 
mean age and VAS score of the patients, in group A, was 32.27±6.15 years and 6.85±1.77 respectively. There 
were 99.2% (n=117) males and 0.8% (n=1) female, in group A. In group B age and VAS score was 30.92±6.68 
years and 7.03±1.86 respectively. There were 93.2% (n=110) males and 6.8% (n=8) females in group B. In group 
C age and VAS score was 32.66±6.42 years and 7.28±1.62 respectively. There were98.3% (n=116) males and 1.7% 
(n=2) females, in group C. (Table-1). 
Group A 
Mouth opening from baseline measurement (before treatment) was 2.34±1.03 mm at week six. After 
complete treatment the mean distance of mouth opening from 1 week to sixth week was 1.8±0.95 mm, 2.79±1.16 
mm, 3.22±1.51 mm, 4.2±1.23 mm, 4.44±1.0 mm and 5.08±1.05 mm respectively in group number A. When mean 
mouth opening values of six weeks (1-6 weeks) were compared with the baseline values, it was found that p-values 
0.000, 0.000, 0.000, 0.000, 0.000 respectively, these values are statistically significant, except week 2 i.e. p=0.438. 
(Table-2) 
Group B 
When mouth opening was compared with before treatment values to week 6 was 4.20±1.26 mm. when 
post treatment values were compared mouth opening, from 1 to 6 weeks, was 1.15±0.83 mm, 2.44±1.14 mm, 
3.47±0.55 mm, 3.84±0.73 mm, 4.47±0.84 mm and 4.5±0.61 mm respectively, in group B. On comparison of mouth 
opening from 1-6 weeks with before treatment values, p-values 0.000, 0.000, 0.000, 0.025, 0.020 respectively 
statistically significant, except week 5 i.e. p=0.853. (Table-3) 
Group C 
When mouth opening was compared with before treatment values to week 6 was 3.40±0.19 mm. After 
treatment the mean mouth opening, from 1 to 6 weeks, was 1.57±1.48 mm, 1.98±0.53 mm, 2.6±0.56 mm, 
3.23±0.80 mm, 3.5±0.96 mm and 4.6±0.94 mm respectively, in group C. On comparison of average mouth opening 
from week 1-6 with before treatment values, it was found p-values 0.000, 0.000, 0.036, 0.013, 0.000 and 0.000 
respectively statistically significant. (Table-4) 
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On comparison of average mouth opening among all the three groups (A, B and C), there was significant 
difference between the groups (p=0.000). (Table-5) 
Table. 1 
Demographic Variables 
Variable Group A  Group B Group C Test of Sig. 
Gender 
M=99.2%, F=0.8% M=93.2%, F=6.8% M=98.3%, 
F=1.7% 
χ2 = 8.096 
p=0.018 
Age 
32.27±6.15 years 30.92±6.68 years 32.66±6.42 years t=1.611 
p=0.108 
VAS Score 
6.85±1.77 7.03±1.86 7.28±1.62 t=-0.749 
p=0.454 
 
Table-2: Mouth opening changes during treatment in A group 
Duration Change Mouth 
Opening (mm) 
Test of Sig. 
Week 1 
1.8±0.95 t=3.764 
p=0.000 
Week 2 
2.79±1.16 t=-0.781 
p=0.438 
Week 3 
3.22±1.51 t=-4.254 
p=0.000 
Week 4 
4.2±1.23 t=-7.206 
p=0.000 
Week 5 
4.44±1.0 t=-8.089 
p=0.000 
Week 6 
5.08±1.05 t=-15.656 
p=0.000 
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Table-3: Mouth opening changes during treatment in B group 
Duration Change Mouth 
Opening (mm) 
Test of Sig. 
Week 1 
1.15±0.83 t=13.584 
p=0.000 
Week 2 
2.44±1.14 t=8.509 
p=0.000 
Week 3 
3.47±0.55 t=5.496 
p=0.000 
Week 4 
3.84±0.73 t=2.306 
p=0.025 
Week 5 
4.47±0.84 t=-0.186 
p=0.853 
Week 6 
4.5±0.61mm t=-2.404 
p=0.020 
 
Table-4: Mouth opening changes during treatment in A group 
Duration Change Mouth 
Opening (mm) 
Test of Sig. 
Week 1 
1.57±1.48 t=12.835 
p=0.000 
Week 2 
1.98±0.53 t=7.525 
p=0.000 
Week 3 
2.6±0.56 t=2.146 
p=0.036 
Week 4 
3.23±0.80 t=-2.588 
p=0.013 
Week 5 
3.5±0.96 t=-4.185 
p=0.000 
Week 6 
4.6±0.94 t=-10.801 
p=0.000 
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Table-5: Comparison of mouth opening between groups at six weeks and baseline 
Time Points 
Compared 
Group Mean±S.D F-Value P-value 
Week o to 
Week 6 
A 2.34±1.03 341.11 0.000 
B 4.20±1.26 
C 3.40±0.19 
 
Discussion: 
Lycopene is main carotenoid mostly found in tomatoes, having potent anticancer activity in variety of cancer (11). 
Antioxidant activity of lycopene have role in treatment of many chronic diseases and in early symptoms. In many 
oral diseases like OSF, leukoplakia and malignant lesions lycopene play an important role for the management 
plan (12). 
 
Nidhi Elizabeth et al (13) conducted a study on comparison of lycopene and multivitamins and concluded that 
when Lycopene was administered combined with intralesional steroids and Hyaluronidase drugs it was found that 
lycopene is too much effective in treatment of mouth opening and its symptoms when used in patients with Oral 
Submucous Fibrosis OSF. 
 
Kaur H et al (14) also conducted a study on this topic and concluded that Lycopene and intralesional steroids and 
Hyaluronidase is significantly effective in treatment of OSF by improving the mouth opening and reducing the 
symptoms of OSF there were no side effects were reported with its use. 
 
Selvam NP et al (15) conducted a study on lycopene and its effectiveness in OSF and concluded that Lycopene in 
combination with intralesional steroids and Hyaluronidase is more effective than any other drug in combination 
or alone which are used in treatment of OSF. 
 
Dipti Singh et al  (16) conducted a study on use of lycopene and intralesional injection of steroids and concluded 
that Lycopene is better than intralesional betamethasone injectable in improvement of mouth opening and 
reduction of burning sensation.  
 
 Katharia et al (17) reported in his study that in the treatment plan of OSMF, with intralesional placental extracts 
the burning sensation improved by 40.2% and Anshumalee N et al (18) reported 54-60% reduction in burning 
sensation with IFN on comparison of both groups it was observed mean burning sensation in Group I was high 
and significant as compared to Group II. P was < 0.001. 
 
Lycopene have an important role in inhibition of hepatic fibrosis in rats and in human fibroblast activity in vitro 
conditions. So, it can be used in the management of OSMF Kitade et al (19). 
 
Kopuri RK et al (20) conducted a study on efficacy of lycopene and concluded that Lycopene have better results 
when compared to curcumin in the management of OSMF, but when studies conducted on larger sample size and 
prolong follow-ups are necessary for better understanding the role of curcumin in the management of OSMF and 
its symptoms. 
 
Conclusion 
When Lycopene used combined with intralesional steroids and Hyaluronidase its effectiveness is better in 
improving the mouth opening its symptoms in patients with Oral Submucous Fibrosis (OSF). It was also found 
that there was no side effects. 
References: 
1. Shamila H, Andrabi SAH, Imtiyaz A. Socio-demographic factors associated with sputum positivity rates 
for Tuberculosis in patients with cough in Srinagar hospital, India. Pacific J Med Sci. 2012;9(2):47-52. 
2. Chole RH, Gondivkar SM, Gadbail AR, Balsaraf S, Chaudhary S, Dhore SV, et al. Review of drug 
treatment of oral submucous fibrosis. Oral oncol. 2012;48(5):393-8. 
Journal of Medicine, Physiology and Biophysics                                                                                                                              www.iiste.org 
ISSN 2422-8427     An International Peer-reviewed Journal DOI: 10.7176/JMPB 
Vol.52, 2019 
 
95 
3. Gupta M, Mishra P, Shrivastava K, Singh N, Singh P. Oral Submucous Fibrosis-Current Concepts of 
Aetiology & its Management. J Applied Dent Med Sci. 2015;1(1):28-39. 
4. Mohammad H, Hadi NI, Younus S, Ahmed F, Younus N. POTENTIALLY SIGNIFICANT 
BIOMARKERS IN ORAL SUBMUCOUS FIBROSIS. Pak J Med Dent. 2015;4(02):51-6. 
5. Ganie SA, Dar TA, Bhat AH, Dar KB, Anees S, Zargar MA, et al. Melatonin: a potential anti-oxidant 
therapeutic agent for mitochondrial dysfunctions and related disorders. Rejuvenation Res. 2016;19(1):21-40. 
6. Asif M, Khodadadi E. Medicinal uses and chemistry of flavonoid contents of some common edible 
tropical plants. J Paramed Sci. 2013;4(3):119-38. 
7. Mouritsen OG. Gastrophysics of the oral cavity. Curr Pharm Des. 2016;22(15):2195-203. 
8. Caffrey PB, Frenkel GD, Mcandrew KL, Marks K. A Model of the Development of Cisplatin Resistance 
in Human Small Cell Lung Cancer Xenografts. In Vivo. 2016;30(6):745-9. 
9. Aslani BA, Ghobadi S. Studies on oxidants and antioxidants with a brief glance at their relevance to the 
immune system. Life sci. 2016;146:163-73. 
10. Burton-Freeman B, Sesso HD. Whole food versus supplement: comparing the clinical evidence of tomato 
intake and lycopene supplementation on cardiovascular risk factors. Adv Nutr.  2014;5(5):457-85. 
11. Singh M, Bagewadi A. Comparison of effectiveness of Calendula officinalis extract gel with lycopene 
gel for treatment of tobacco-induced homogeneous leukoplakia: A randomized clinical trial. Int J Pharm Investig. 
2017;7(2):88-93. 
12. Nayak A, Anitha B, Bhattacharya A, Podder S. EFFICACY OF LYCOPENE IN COMBINATION WITH 
VITAMIN E IN MANAGEMENT OF ORAL SUBMUCOUS FIBROSIS-A CLINICAL PROSPECTIVE 
STUDY. J  Adv Med Dent Sci Res. 2015;3(3):21-25. 
13. Elizabeth N, Gurumani S, Bala GA, Tukalan G. A comparative study between management of oral 
submucous fibrosis. J Evolution Med Dent Sci. 2014;3(47):11344-9. 
14. Kaur H, Singh A, Goyal S. Use of lycopene in the management of oral submucous fibrosis: a clinical 
study. International Journal of Medical and Dental Sciences. 2016 July; 5(2): 1229-35. 
15. Selvam NP, Dayanand AA. Lycopene in the management of oral submucous fibrosis. Asian J Pharm Clin 
Res. 2013;6(3):58-61. 
16. Singh D, Shashikanth MC, Misra N, Agrawal S. Lycopene and intralesional betamethasone injections in 
the management of oral submucous fibrosis. J Indian Acad Oral Med Radiol. 2014;26(3):264-8. 
17. Katharia SK, Singh SP, Kulshreshtha VK. The effects of placental extract in management of oral-submucous 
fibrosis. Indian J Pharm. 1992;24(3):181-3. 
18. Anshumalee N, Shashikanth MC, Shambulingappa P, Deepak U. Lycopene: A promising antioxidant. J Indian 
Acad Oral Med Radiol 2007;19(4):458-63. 
19. Kitade Y, Watanabe S, Masaki T, Nishioka M, Nishino H. Inhibition of liver fibrosis in LEC rats by a 
carotenoid, lycopene, or a herbal medicine, Sho-saiko-to. Hepatol Res. 2002;22(3):196-205. 
20. Kopuri RK. A Comparative Study of the Clinical Efficacy of Lycopene and Curcumin in the Treatment of Oral 
Submucous Fibrosis using Ultrasonography. J Int Oral Health. 2016; 8(6):687-91. 
 
 
 
